Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances.

Abstract:

:Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of B-cell malignancies, and it is so popular that gross sales have rapidly grown to more than 230 billion dollars in just 6 years, with annual sales exceeding 80 billion dollars; it also became one of the five top-selling medicines in the world. Numerous clinical trials of BTK inhibitors in cancers were initiated in the last decade, and ~73 trials were intensively announced or updated with extended follow-up data in the most recent 3 years. In this review, we summarized the significant milestones in the preclinical discovery and clinical development of BTK inhibitors to better understand the clinical and commercial potential as well as the directions being taken. Furthermore, it also contributes impactful lessons regarding the discovery and development of other novel therapies.

journal_name

Leukemia

journal_title

Leukemia

authors

Wen T,Wang J,Shi Y,Qian H,Liu P

doi

10.1038/s41375-020-01072-6

subject

Has Abstract

pub_date

2020-10-29 00:00:00

eissn

0887-6924

issn

1476-5551

pii

10.1038/s41375-020-01072-6

pub_type

杂志文章,评审

相关文献

LEUKEMIA文献大全
  • Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.

    abstract::To determine the clinical significance of minimal residual disease (MRD) in patients with prognostically relevant subtypes of childhood acute lymphoblastic leukemia (ALL), we analyzed data from 488 patients treated in St Jude Total Therapy Study XV with treatment intensity based mainly on MRD levels measured during re...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.234

    authors: Pui CH,Pei D,Raimondi SC,Coustan-Smith E,Jeha S,Cheng C,Bowman WP,Sandlund JT,Ribeiro RC,Rubnitz JE,Inaba H,Gruber TA,Leung WH,Yang JJ,Downing JR,Evans WE,Relling MV,Campana D

    更新日期:2017-02-01 00:00:00

  • CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.

    abstract::The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the identification and elimination of low-level disease persistence, termed "minimal residual disease". The phenomenon of disease persistence suggests that despite tar...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0684-5

    authors: Kinstrie R,Horne GA,Morrison H,Irvine D,Munje C,Castañeda EG,Moka HA,Dunn K,Cassels JE,Parry N,Clarke CJ,Scott MT,Clark RE,Holyoake TL,Wheadon H,Copland M

    更新日期:2020-06-01 00:00:00

  • Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation.

    abstract::Lack of apoptosis has been linked to prolonged survival of malignant B cells expressing bcl-2. The aim of the present study was to analyze the amount of bcl-2 protein expressed along normal human B-cell maturation and to establish the frequency of aberrant bcl-2 expression in B-cell malignancies. In normal bone marrow...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403231

    authors: Menendez P,Vargas A,Bueno C,Barrena S,Almeida J,De Santiago M,López A,Roa S,San Miguel JF,Orfao A

    更新日期:2004-03-01 00:00:00

  • Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice.

    abstract::The efficacy of antibody-based immunotherapy is due to the activation of apoptosis, the engagement of antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity (CDC). We developed a novel strategy to enhance CDC using bispecific antibodies (bsAbs) that neutralize the C-regulators CD55 and CD59 to ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.185

    authors: Macor P,Secco E,Mezzaroba N,Zorzet S,Durigutto P,Gaiotto T,De Maso L,Biffi S,Garrovo C,Capolla S,Tripodo C,Gattei V,Marzari R,Tedesco F,Sblattero D

    更新日期:2015-02-01 00:00:00

  • Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.

    abstract::Identification of agents that target human leukemia stem cells is an important consideration for the development of new therapies. The present study demonstrates that rocaglamide and silvestrol, closely related natural products from the flavagline class of compounds, are able to preferentially kill functionally define...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.93

    authors: Callahan KP,Minhajuddin M,Corbett C,Lagadinou ED,Rossi RM,Grose V,Balys MM,Pan L,Jacob S,Frontier A,Grever MR,Lucas DM,Kinghorn AD,Liesveld JL,Becker MW,Jordan CT

    更新日期:2014-10-01 00:00:00

  • Therapeutic strategies for postremission treatment in childhood acute myeloid leukemia (AML). The AIEOP experience 1987-1991.

    abstract::From 1987 to 1990, intensive postremission chemotherapy was compared to autologous bone marrow transplant in previously untreated children with AML who received identical induction therapy with two courses of Daunorubicin (DNR) and conventional dose ARA-C (protocol AIEOP LAM 87). Overall, 121 of the 155 eligible patie...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Amadori S,Giona F,Giuliano M,Moleti ML,Pession A,Rolla M,Rondelli R,Testi AM,Mandelli F

    更新日期:1992-01-01 00:00:00

  • Amplification and sequencing of genomic breakpoints located within the M-bcr region by Vectorette-mediated polymerase chain reaction.

    abstract::The polymerase chain reaction (PCR) cannot be used to amplify the breakpoint in the chimaeric BCR-ABL gene in CML and acute leukaemias due to the large variation in the sites of breakpoint in the BCR gene (within a 5.8 kb region) and in the ABL gene (within a 150 kb region). The disease state is usually monitored usin...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Mills KI,Sproul AM,Ogilvie D,Elvin P,Leibowitz D,Burnett AK

    更新日期:1992-05-01 00:00:00

  • Mesenchymal stem cells in suppression or progression of hematologic malignancy: current status and challenges.

    abstract::Mesenchymal stem cells (MSCs) are known for being multi-potent. However, they also possess anticancer properties, which has prompted efforts to adapt MSCs for anticancer therapies. However, MSCs have also been widely implicated in pathways that contribute to tumor growth. Numerous studies have been conducted to adapt ...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-018-0373-9

    authors: Lee MW,Ryu S,Kim DS,Lee JW,Sung KW,Koo HH,Yoo KH

    更新日期:2019-03-01 00:00:00

  • Complex landscape of alternative splicing in myeloid neoplasms.

    abstract::Myeloid neoplasms are characterized by frequent mutations in at least seven components of the spliceosome that have distinct roles in the process of pre-mRNA splicing. Hotspot mutations in SF3B1, SRSF2, U2AF1 and loss of function mutations in ZRSR2 have revealed widely different aberrant splicing signatures with littl...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-1002-y

    authors: Hershberger CE,Moyer DC,Adema V,Kerr CM,Walter W,Hutter S,Meggendorfer M,Baer C,Kern W,Nadarajah N,Twardziok S,Sekeres MA,Haferlach C,Haferlach T,Maciejewski JP,Padgett RA

    更新日期:2020-08-04 00:00:00

  • Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.

    abstract::Small-molecule multi-targeted cyclin-dependent kinase (CDK) inhibitors (CDKIs) are of particular interest due to their potent antitumor activity independent of p53 gene alterations. P53 deletion is associated with a very poor prognosis in multiple myeloma (MM). In this regard, we tested the anti-MM activity of RGB-286...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.194

    authors: Cirstea D,Hideshima T,Santo L,Eda H,Mishima Y,Nemani N,Hu Y,Mimura N,Cottini F,Gorgun G,Ohguchi H,Suzuki R,Loferer H,Munshi NC,Anderson KC,Raje N

    更新日期:2013-12-01 00:00:00

  • Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?

    abstract::C-mpl ligand acts primarily as a lineage-specific hematopoietic growth factor by promoting proliferation of megakaryocyte precursors and their differentiation into megakaryocytes and platelets. In addition to the ability of c-mpl ligand to support megakaryocytic development from CD34+ precursor cells, several lines of...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Hofmann WK,Ottmann OG,Hoelzer D

    更新日期:1999-01-01 00:00:00

  • The diagnositc significance of Myf-3 hypermethylation in malignant lymphoproliferative disorders.

    abstract::Deregulated methylation of cytosine in DNA is a frequent finding in malignancy that is reflected by general genomic hypomethylation and regional hypermethylation that includes the myogenic gene Myf-3. In this study of 198 DNA samples from 186 patients with a wide range of lymphoproliferative disorders (LPD), the methy...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402080

    authors: Taylor JM,Kay PH,Spagnolo DV

    更新日期:2001-04-01 00:00:00

  • JAK inhibitors suppress t(8;21) fusion protein-induced leukemia.

    abstract::Oncogenic mutations in components of the JAK/STAT pathway, including those in cytokine receptors and JAKs, lead to increased activity of downstream signaling and are frequently found in leukemia and other hematological disorders. Thus, small-molecule inhibitors of this pathway have been the focus of targeted therapy i...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.197

    authors: Lo MC,Peterson LF,Yan M,Cong X,Hickman JH,Dekelver RC,Niewerth D,Zhang DE

    更新日期:2013-12-01 00:00:00

  • Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.

    abstract::In diffuse large B-cell lymphoma (DLBCL), the clinical and biological significance of concordant and discordant bone marrow (BM) involvement have not been well investigated. We evaluated 712 de novo DLBCL patients with front-line rituximab-containing treatment, including 263 patients with positive and 449 with negativ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.222

    authors: Yao Z,Deng L,Xu-Monette ZY,Manyam GC,Jain P,Tzankov A,Visco C,Bhagat G,Wang J,Dybkaer K,Tam W,Hsi ED,van Krieken JH,Ponzoni M,Ferreri AJM,Møller MB,Winter JN,Piris MA,Fayad L,Liu Y,Song Y,Orlowski RZ,Kantarjia

    更新日期:2018-02-01 00:00:00

  • Somatic hypermutation targeting to intrinsic hotspots of immunoglobulin genes in follicular lymphoma and multiple myeloma.

    abstract::In this study, we analyzed the targeting of the somatic hypermutation (SHM) mechanism at specific hotspot sequence motifs in the V(H) and Vkappa genes of 10 follicular lymphoma (FL) cases and the Vkappa and Vlambda genes of 11 kappa- and six lamda-light chain expressing multiple myeloma (MM) cases. These sequences wer...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402258

    authors: Belessi C,Stamatopoulos K,Stavroyianni N,Zoi K,Papadaki T,Kosmas C

    更新日期:2001-11-01 00:00:00

  • Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital.

    abstract::We present the long-term results of three consecutive clinical trials (Total Therapy studies 11, 12 and 13A) conducted for children with newly diagnosed acute lymphoblastic leukemia (ALL) between 1984 and 1994. In study 11 (1984-1988), the overall event-free survival rates (+/-1 s.e.) were 71.8 +/- 2.4% and 69.3 +/- 2...

    journal_title:Leukemia

    pub_type: 杂志文章,meta分析

    doi:10.1038/sj.leu.2401938

    authors: Pui CH,Boyett JM,Rivera GK,Hancock ML,Sandlund JT,Ribeiro RC,Rubnitz JE,Behm FG,Raimondi SC,Gajjar A,Razzouk B,Campana D,Kun LE,Relling MV,Evans WE

    更新日期:2000-12-01 00:00:00

  • Antibodies directed against a variable and neutralizable region of the HTLV-I envelope surface glycoprotein.

    abstract::The majority of neutralizing antibodies of HTLV-I are directed against linear epitopes of the envelope surface glycoprotein (gp46) in the immunodominant region 175-199. Although gp46 presents a remarkable degree of conservation, the substitution of the proline at position 192 by a serine is described for 10 isolates a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Londos-Gagliardi D,Armengaud MH,Freund F,Dalibart R,Moze E,Huet S,Legrand E,Guillemain BJ

    更新日期:1997-04-01 00:00:00

  • HTLV-I Tax trans-activation and cell growth signaling.

    abstract::We have cloned two genes for cell surface molecules, capable of delivering the intracellular signals, which are modulated for their expression by Tax. One is the gamma chain of the interleukin-2 (IL-2) receptor which is suggested to be critical for IL-2-dependent growth of human T-cell leukemia virus type I (HTLV-I) i...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Nakamura M,Takasawa N,Ohbo K,Higashimura N,Ohtani K,Tanaka Y,Sugamura K

    更新日期:1997-04-01 00:00:00

  • Acute myeloblastic leukemia with t(8;21) following Philadelphia positive acute lymphoblastic leukemia.

    abstract::A patient with Philadelphia positive (Ph'+) acute lymphoblastic leukemia (ALL), in remission for over 4 years, developed an acute myeloblastic leukemia (AML), M2-type. During the second disease, the blast cells displayed a typical t(8;21)(q22;q22) translocation, in the absence of the Ph' chromosome. This is the first ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: De Cuia MR,Alimena G,Gastaldi R,Spiriti MA,Giona F,Mancini M,Mandelli F

    更新日期:1989-04-01 00:00:00

  • Colony-forming unit-megakaryocyte (CFR-meg) numbers and serum thrombopoietin concentrations in thrombocytopenic disorders: an inverse correlation in myelodysplastic syndromes.

    abstract::We studied both serum-free colony-forming unit-megakaryocyte (CFU-meg) numbers and serum thrombopoietin (TPO) levels in 14 patients with aplastic anemia (AA), 37 patients with myelodysplastic syndromes (MDS) and 23 patients with idiopathic thrombocytopenic purpura (ITP) to assess thrombopoiesis in these thrombocytopen...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401898

    authors: Wang W,Matsuo T,Yoshida S,Mori H,Miyazaki Y,Kuriyama K,Tomonaga M

    更新日期:2000-10-01 00:00:00

  • Expression and regulation of the evi-1 gene in the human factor-dependent leukemia cell line, UCSD/AML1.

    abstract::The human factor-dependent leukemia cell line UCSD/AML1 contains the t(3;3) (q21;q26) characteristic of the syndrome of acute leukemia with high platelets. The human homologue of the murine leukemia oncogene evi-1 was recently localized to chromosome 3q24-3q28 and transcription of evi-1 is a frequent event in mouse-re...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Oval J,Smedsrud M,Taetle R

    更新日期:1992-05-01 00:00:00

  • The human lysozyme gene undergoes stepwise demethylation during phagocyte maturation.

    abstract::The lysozyme (LZM) gene provides a very useful model for studies of phagocyte maturation, because its protein synthesis is increased during myelopoiesis and thus most abundant in terminally differentiated and activated phagoyctes. LZM gene expression and DNA methylation were examined in various normal and transformed ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400693

    authors: Lübbert M,Henschler R,Kreutz M,Andreesen R,Mertelsmann R,Herrmann F

    更新日期:1997-07-01 00:00:00

  • Sensitive and reproducible detection of occult disease in patients with follicular lymphoma by PCR amplification of t(14;18) both pre- and post-treatment.

    abstract::The t(14;18) chromosomal translocation occurs in most follicular non-Hodgkin's lymphomas and places the Bcl-2 gene on chromosome 18q21 into the immunoglobulin JH region on chromosome 14q32. This translocation can be exploited to detect clonal malignant cells bearing this genetic alteration. A polymerase chain reaction...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Berinstein NL,Jamal HH,Kuzniar B,Klock RJ,Reis MD

    更新日期:1993-01-01 00:00:00

  • TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia.

    abstract::Abnormal karyotypes are common in cancer cells and frequently observed in acute myeloid leukemia (AML), in which complex karyotype aberrations are associated with poor prognosis. How exactly abnormal karyotypes arise and are propagated in AML is unclear. TP53 mutations and deletions are frequent in complex karyotype A...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0550-5

    authors: Cazzola A,Schlegel C,Jansen I,Bochtler T,Jauch A,Krämer A

    更新日期:2019-11-01 00:00:00

  • Pathogenesis and prevention of HTLV-1-associated diseases.

    abstract::HTLV-1 is an important factor involved in various diseases including adult T-cell leukemia/lymphoma and HTLV-1 associated myelopathy/tropical spastic paraparesis. Amount of HTLV-1 provirus integrated in human peripheral blood mononuclear cells might be a candidate for a risk factor in the manifestation of HTLV-1 assoc...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Miwa M,Kushida S,Maeda N,Fang J,Kawamura T,Kameyama T,Uchida K

    更新日期:1997-04-01 00:00:00

  • Clinical activity of arsenic trioxide for the treatment of multiple myeloma.

    abstract::Arsenic has been used since ancient times as a therapeutic agent. However, until recently its use in modern medicine has been restricted to the treatment of a limited number of parasitic infections. In the early 1990s, reports from China described impressive results with arsenic trioxide in patients with de novo, rela...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2402599

    authors: Munshi NC,Tricot G,Desikan R,Badros A,Zangari M,Toor A,Morris C,Anaissie E,Barlogie B

    更新日期:2002-09-01 00:00:00

  • Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.

    abstract::We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in the first 3 years fol...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.29

    authors: Short KD,Rajkumar SV,Larson D,Buadi F,Hayman S,Dispenzieri A,Gertz M,Kumar S,Mikhael J,Roy V,Kyle RA,Lacy MQ

    更新日期:2011-06-01 00:00:00

  • Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements.

    abstract::Monitoring of BCR-ABL transcripts has become established practice in the management of chronic myeloid leukemia. However, nucleic acid amplification techniques are prone to variations which limit the reliability of real-time quantitative PCR (RQ-PCR) for clinical decision making, highlighting the need for standardizat...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404716

    authors: Saldanha J,Silvy M,Beaufils N,Arlinghaus R,Barbany G,Branford S,Cayuela JM,Cazzaniga G,Gonzalez M,Grimwade D,Kairisto V,Miyamura K,Lawler M,Lion T,Macintyre E,Mahon FX,Muller MC,Ostergaard M,Pfeifer H,Saglio G,Saw

    更新日期:2007-07-01 00:00:00

  • Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) stu

    abstract::Reliable detection of JAK2-V617F is critical for accurate diagnosis of myeloproliferative neoplasms (MPNs); in addition, sensitive mutation-specific assays can be applied to monitor disease response. However, there has been no consistent approach to JAK2-V617F detection, with assays varying markedly in performance, af...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2013.219

    authors: Jovanovic JV,Ivey A,Vannucchi AM,Lippert E,Oppliger Leibundgut E,Cassinat B,Pallisgaard N,Maroc N,Hermouet S,Nickless G,Guglielmelli P,van der Reijden BA,Jansen JH,Alpermann T,Schnittger S,Bench A,Tobal K,Wilkins B,Cu

    更新日期:2013-10-01 00:00:00

  • Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.

    abstract::Alterations in the FLT3 gene, including internal tandem duplications (ITDs) and D835 mutations occur frequently in acute myelogenous leukemia. We investigated the prevalence and clinico-biological correlations of FLT3 ITDs and D835 mutations in 90 patients with acute promyelocytic leukemia (APL) receiving the AIDA pro...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402723

    authors: Noguera NI,Breccia M,Divona M,Diverio D,Costa V,De Santis S,Avvisati G,Pinazzi MB,Petti MC,Mandelli F,Lo Coco F

    更新日期:2002-11-01 00:00:00